Isis Pharmaceuticals and Nitto Denko said this week that that have developed a new solid support for the manufacture of oligonucleotides.

According to the companies, solid support is the base structure used in the synthesis of oligonucleotides such as siRNAs. The new product, they added, is cheaper to manufacture than currently used solid supports and has the potential to increase yield.

The product will be marketed by Kinovate Life Sciences, a subsidiary of Nitto Denko. Isis will receive royalties on sales.